Eli Lilly has announced positive results from a late-stage clinical trial of retatrutide, a next-generation weight-loss medication demonstrating significant reductions in body mass.

禮來公司公布了 Retatrutide 後期臨床試驗的正面結果，這是一款能顯著降低體重的新一代減重藥物。

The clinical evaluation of retatrutide, a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon, involved approximately 2,300 adults with obesity or overweight status. Data indicate that the 12mg dosage resulted in an average weight reduction of 28.3% over 80 weeks, with 45.3% of participants achieving a loss of 30% or more. In an extended study of patients with a BMI of 35 or higher, weight loss averaged 30.3% over 104 weeks. These metrics are noted to be comparable to outcomes typically associated with bariatric surgery and exceed the efficacy of existing GLP-1 and GIP agonists such as Zepbound and Wegovy.

Retatrutide 是一種針對 GLP-1、GIP 及 glucagon 的三受體激素激動劑，此次臨床評估涉及約 2,300 名肥胖或超重的成年人。數據顯示，使用 12mg 劑量在 80 週內平均減重 28.3%，其中 45.3% 的參與者減重達 30% 或更多。在一項針對 BMI 35 或以上患者的延伸研究中，104 週內的平均減重為 30.3%。這些指標被認為與典型的減重手術結果相當，並超過了現有的 GLP-1 和 GIP 激動劑（如 Zepbound 和 Wegovy）的療效。

Regarding safety and tolerability, the administration of retatrutide was associated with gastrointestinal adverse effects, including nausea, diarrhea, and constipation, with incidence rates increasing alongside dosage. Specifically, 42.4% of the highest-dose group reported nausea. Other observed effects included upper respiratory tract infections, urinary tract infections, and dysesthesia. However, a 4mg dose demonstrated a tolerability profile that exceeded expectations, with discontinuation rates lower than those of the placebo group. Eli Lilly reported no evidence of cardiac or hepatic complications.

關於安全性與耐受性，使用 Retatrutide 與胃腸道不良反應相關，包括噁心、腹瀉和便秘，且發生率隨劑量增加而上升。具體而言，最高劑量組中 42.4% 的受試者報告有噁心感。其他觀察到的副作用包括上呼吸道感染、尿路感染及感覺異常。然而，4mg 劑量展現出超出預期的耐受性，中斷治療率低於安慰劑組。禮來公司報告稱，未發現心臟或肝臟併發症的證據。

From a strategic perspective, the development of retatrutide is intended to consolidate Eli Lilly's market dominance in the obesity and diabetes sector, where it held a 60.1% U.S. market share in Q1. This objective is pursued amidst a broader industry trend toward peptide-based therapies. While pharmaceutical giants focus on FDA-approved pathways, a parallel market for compounded peptides has emerged to address dosing flexibility and supply shortages, leading to regulatory tension between commercial entities and compounding pharmacies. Concurrently, Novo Nordisk has sought a rapprochement with the triple-agonist mechanism by acquiring rights to an experimental drug from United Laboratories International, although this candidate remains in an earlier developmental stage than retatrutide.

從戰略角度來看，研發 Retatrutide 旨在鞏固禮來公司在肥胖與糖尿病領域的市場主導地位，該公司第一季度在美國的市場份額為 60.1%。這一目標是在整個行業趨向多肽療法的趨勢下推進的。當製藥巨頭專注於 FDA 批准的途徑時，一個調配多肽的平行市場隨之興起，以解決劑量靈活性和供應短缺問題，導致商業實體與調配藥局之間產生監管緊張關係。與此同時，諾和諾德 (Novo Nordisk) 透過從 United Laboratories International 收購一款實驗性藥物的權利，試圖追趕三受體激動機制，儘管該候選藥物的開發階段早於 Retatrutide。

Retatrutide has demonstrated superior weight-loss efficacy in Phase 3 trials, and Eli Lilly intends to seek FDA approval as early as the current calendar year.

Retatrutide 在第三期試驗中展現出卓越的減重療效，禮來公司打算最快在今年內申請 FDA 批准。